Announced Mon, 18 May · 15:04 IST

Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the audited financial ....

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-8.5%1-day move
₹26.50
prior close
₹26.50
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+0.0-3.8-8.5-4.2+0.6+0.2+16.4+13.2
Up moveDown movePending
AI summary

The company has informed BSE that its Board of Directors meeting is scheduled for May 29, 2026 to consider and approve the audited standalone financial results for Q4 and the financial year ended March 31, 2026. The trading window for directors, KMPs, promoters, and designated persons has been closed from April 1, 2026 and will remain closed until 48 hours after the results are made public. This is a routine regulatory intimation required under SEBI listing regulations.

Likely market impact

This is a standard pre-result announcement. The actual financial performance and any red flags will only be visible when the results are disclosed on May 29, 2026. Shareholders should await the formal results announcement for any assessment of company health.